A detailed history of Td Asset Management Inc transactions in Relay Therapeutics, Inc. stock. As of the latest transaction made, Td Asset Management Inc holds 358,656 shares of RLAY stock, worth $2.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
358,656
Previous 467,966 23.36%
Holding current value
$2.49 Million
Previous $5.15 Million 42.24%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

SELL
$7.5 - $12.07 $819,825 - $1.32 Million
-109,310 Reduced 23.36%
358,656 $2.98 Million
Q4 2023

Feb 12, 2024

SELL
$6.01 - $11.48 $177,439 - $338,935
-29,524 Reduced 5.93%
467,966 $5.15 Million
Q3 2023

Oct 27, 2023

BUY
$8.24 - $12.97 $1.93 Million - $3.03 Million
233,983 Added 88.8%
497,490 $4.18 Million
Q2 2023

Aug 09, 2023

BUY
$9.99 - $18.27 $466,433 - $853,026
46,690 Added 21.53%
263,507 $3.31 Million
Q1 2023

May 10, 2023

BUY
$15.0 - $22.76 $1.4 Million - $2.12 Million
93,255 Added 75.47%
216,817 $3.57 Million
Q4 2022

Feb 06, 2023

BUY
$14.16 - $24.02 $59,472 - $100,884
4,200 Added 3.52%
123,562 $1.85 Million
Q3 2022

Nov 07, 2022

BUY
$18.07 - $31.37 $349,925 - $607,480
19,365 Added 19.37%
119,362 $2.76 Million
Q1 2022

May 10, 2022

BUY
$20.26 - $32.36 $18,193 - $29,059
898 Added 0.91%
99,997 $2.99 Million
Q4 2021

Feb 10, 2022

BUY
$26.0 - $37.03 $1.87 Million - $2.67 Million
72,092 Added 266.94%
99,099 $3.04 Million
Q3 2021

Nov 09, 2021

BUY
$29.75 - $37.99 $142,800 - $182,352
4,800 Added 21.61%
27,007 $852,000
Q1 2021

May 14, 2021

BUY
$32.52 - $61.53 $125,754 - $237,936
3,867 Added 21.09%
22,207 $768,000
Q3 2020

Nov 10, 2020

BUY
$32.81 - $45.1 $601,735 - $827,134
18,340 New
18,340 $781,000

Others Institutions Holding RLAY

About Relay Therapeutics, Inc.


  • Ticker RLAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 120,219,000
  • Market Cap $834M
  • Description
  • Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...
More about RLAY
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.